ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors...

[cafead]

via Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion.

article source